Asempa Tomefa E, Avery Lindsay M, Kidd James M, Kuti Joseph L, Nicolau David P
Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, CT.
Am J Health Syst Pharm. 2018 Jul 15;75(14):1048-1056. doi: 10.2146/ajhp170839. Epub 2018 Jun 12.
The results of a study to determine the physical compatibility of plazomicin sulfate solution during simulated Y-site administration with 92 i.v. drugs are reported.
Plazomicin injection solution (500 mg/10 mL) was diluted in 0.9% sodium chloride or 5% dextrose for injection to a final volume of 50 mL (final plazomicin concentration, 24 mg/mL), consistent with a 15-mg/kg dose administered to an 80-kg patient (i.e., 1,200 mg). All other i.v. drugs were reconstituted according to manufacturers' recommendations and diluted with 0.9% sodium chloride or 5% dextrose for injection to the upper range of concentrations used clinically. Y-site conditions were simulated by mixing 5 mL of plazomicin solution with 5 mL of tested drug solutions in a 1:1 ratio. Solutions were assessed for visual (via color and Tyndall beam testing), turbidity (using a laboratory-grade turbidimeter), and pH changes over a 60-minute observation period. Incompatibility was defined a priori as precipitation, color change, a positive Tyndall test, or a turbidity change of ≥0.5 nephelometric turbidity units at any time during the 60-minute observation period.
Plazomicin was physically compatible with 79 of the 92 drugs tested. Determinations of physical incompatibility with plazomicin were made for 13 drugs: albumin, amiodarone, amphotericin B deoxycholate, anidulafungin, calcium chloride, daptomycin, esomeprazole, heparin, levofloxacin, methylprednisolone, micafungin, phenytoin, and propofol, CONCLUSION: Plazomicin at a concentration of 24 mg/mL was physically compatible with 85% of the drugs tested, including 31 of 36 antimicrobial agents.
报告一项关于硫酸普拉唑米星溶液在模拟Y型接口给药时与92种静脉注射药物的物理相容性研究结果。
将普拉唑米星注射液(500mg/10mL)用0.9%氯化钠注射液或5%葡萄糖注射液稀释至最终体积50mL(普拉唑米星最终浓度为24mg/mL),这与给一名80kg患者静脉注射15mg/kg剂量(即1200mg)一致。所有其他静脉注射药物均按照制造商的建议进行复溶,并用0.9%氯化钠注射液或5%葡萄糖注射液稀释至临床使用浓度的上限。通过将5mL普拉唑米星溶液与5mL受试药物溶液按1:1比例混合来模拟Y型接口给药情况。在60分钟观察期内,对溶液进行外观(通过颜色和丁达尔光束测试)、浊度(使用实验室级浊度仪)和pH值变化评估。预先将不相容定义为在60分钟观察期内任何时间出现沉淀、颜色变化、丁达尔试验阳性或浊度变化≥0.5比浊法浊度单位。
普拉唑米星与92种受试药物中的79种在物理上相容。确定了与普拉唑米星存在物理不相容的13种药物:白蛋白、胺碘酮、两性霉素B脱氧胆酸盐、阿尼芬净、氯化钙、达托霉素、埃索美拉唑、肝素、左氧氟沙星、甲泼尼龙、米卡芬净、苯妥英和丙泊酚。
浓度为24mg/mL的普拉唑米星与85%的受试药物在物理上相容,包括36种抗菌药物中的31种。